Zobrazeno 1 - 10
of 187
pro vyhledávání: '"Keith Latham"'
Autor:
Keith Latham
Publikováno v:
Molecular Reproduction and Development. 90:169-200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef5f99012cc6d4541785f26a61c5b9b9
https://doi.org/10.1002/mrd.23676
https://doi.org/10.1002/mrd.23676
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Stem Cell Reports, Vol 6, Iss 4, Pp 447-455 (2016)
The reprogramming factors OCT4, SOX2, KLF4, and MYC (OSKM) can reactivate the pluripotency network in terminally differentiated cells, but also regulate expression of non-pluripotency genes in other contexts, such as the mouse primitive endoderm. The
Externí odkaz:
https://doaj.org/article/603176453af64ea3913fb1da216505ad
Autor:
Kaitlin Rose Karl, Peter Schall, Zaramasina Clark, James Ireland, Meghan Ruebel, Keith Latham
Publikováno v:
Endocrinology. 163
High follicle-stimulating hormone (FSH) doses during ovarian stimulation protocols for assisted reproductive technologies (ART) are detrimental to ovulatory follicle function and oocyte quality. However, the mechanisms are unclear. In a small ovarian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d87bb988d5c11f4a765ef9b8ea33f88
https://doi.org/10.1210/endocr/bqac100
https://doi.org/10.1210/endocr/bqac100
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
PLoS ONE, Vol 7, Iss 10 (2012)
Externí odkaz:
https://doaj.org/article/844ec63be76d4825b5d8bebf6290c83f
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e22197 (2011)
Global activation of the embryonic genome (EGA), one of the most critical steps in early mammalian embryo development, is recognized as the time when interspecies somatic cell nuclear transfer (iSCNT) embryos fail to thrive.In this study, we analyzed
Externí odkaz:
https://doaj.org/article/c9da0816154e4380a3f252c7bb41545c
Autor:
Eric T, Wittbrodt, James M, Eudicone, Kelly F, Bell, Devin M, Enhoffer, Keith, Latham, Jennifer B, Green
Publikováno v:
The American journal of managed care. 25(4)
The authors of the manuscript "Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population" respond to a letter to the editor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e48bb9ac3c210ac2eb1edffab32ccb05
https://pubmed.ncbi.nlm.nih.gov/30986012
https://pubmed.ncbi.nlm.nih.gov/30986012
Autor:
Eric T, Wittbrodt, James M, Eudicone, Kelly F, Bell, Devin M, Enhoffer, Keith, Latham, Jennifer B, Green
Publikováno v:
The American journal of managed care. 24
Cardiovascular outcomes trials (CVOTs) for evaluating the safety of novel antidiabetic agents are required by the FDA. CVOTs vary in their design and inclusion criteria, making it difficult to evaluate their applicability to the general population. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::80f3f54238d514486e5ef86029db4e5b
https://pubmed.ncbi.nlm.nih.gov/30986013
https://pubmed.ncbi.nlm.nih.gov/30986013
Autor:
Eric T, Wittbrodt, James M, Eudicone, Kelly F, Bell, Devin M, Enhoffer, Keith, Latham, Jennifer B, Green
Publikováno v:
The American journal of managed care. 24
Guidance to industry from the FDA requires studies to evaluate the cardiovascular safety of novel type 2 diabetes (T2D) medications. Although the objectives of such cardiovascular outcomes trials (CVOTs) are similar, differences in features such as e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b7b47559786277b6bb76beb8a1a305bc
https://pubmed.ncbi.nlm.nih.gov/29693360
https://pubmed.ncbi.nlm.nih.gov/29693360